Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07505732

Information-providing Chatbot

This study aims to develop and examine the feasibility and preliminary effectiveness of an AI-based sarcoma chatbot building on ChatGPT (ASCC) to address the information needs of sarcoma patients. We hypothesized: 1) the ASCC will demonstrate good usability; 2) the study will be feasible in terms of all feasibility indicators; 3) the experimental group will report improved satisfaction and self-efficacy, decreased anxiety and stress than the control groups upon completion of the intervention. The ASCC will be developed using a co-design approach. A pilot randomized controlled trial will then be conducted in the three oncology wards of collaborative hospitals. Seventy-eight sarcoma patients will be recruited and randomized to the experimental group (n=39) and the control group (n=39). The experimental group will use the ASCC available 24/7 via voice or text for disease-related questions for one month while the control group will receive usual care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Sarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) diagnosed with soft tissue sarcoma;
  • (2) receiving active treatment at any stage;
  • (3) aged≥18 years;
  • (4) able to speak Cantonese, Mandarin and English;
  • (5) access to an electronic device enabling ASCC use

Exclusion criteria

  • (1) patients with unstable physical or mental conditions;
  • (2) inability to communicate logically;
  • (3) using chatbots (e.g., ChatGPT, Deepseek) for sarcoma information in the last month;
  • (4) mental health disorders documented by the medical system

Treatment and study plan

ASCC (sarcoma-specific AI chatbot)

Other

The participants in the experimental group will access the ASCC via a webpage alongside standard information from health professionals for one month (15 minutes weekly).

Routine Clinical Care

Other

Participants in the control group will receive routine clinical care, including standard information from doctor-patient consultations (e.g., diagnosis, treatment, medical tests) and hospital provided sarcoma and treatment leaflet.

Primary outcomes

  1. Screening rate

    Time frame: During the enrollment period of this project.

    Calculated by dividing the number of sarcoma patients screened by the research team by the number of sarcoma patients.

  2. Eligibility rate

    Time frame: During the enrollment period of this project.

    Calculated by dividing the number of participants who are eligible by the number who are screened.

  3. Consent rate

    Time frame: During the enrollment period of this project.

    Calculated by dividing the number of participants who were randomized into intervention and control groups by those provide consent.

  4. Randomization rate

    Time frame: During the enrollment period of this project.

    Calculated by dividing the number of participants who consent to join the study by the number who are eligible.

  5. Attendance rate

    Time frame: Baseline and immediately after intervention (T1)

    Calculated by dividing the number of participants who complete the intervention by those who are randomised

  6. Retention rate

    Time frame: Baseline and immediately after intervention (T1)

    Calculated by dividing the number of participants who remain in the study by those who are randomized. This will be calculated by groups.

  7. Completion rate

    Time frame: Baseline and immediately after intervention (T1)

    Calculated by dividing the number of participants who returned questionnaires by the number of questionnaires distributed. Calculated by dividing the number of participants who remain in the study by those who are randomized. This will be calculated by groups.

  8. Proportion of missing data

    Time frame: Baseline and immediately after intervention (T1)

    Calculated as the percentage of missing values in the dataset. Unknown or blank values will be considered missing values.

  9. Adverse events

    Time frame: immediately after intervention (T1)

    Adverse events are defined as unfavourable and unintended events that are not present, or appear to have worsened during the study.

Secondary outcomes

  1. Information satisfaction

    Time frame: Baseline and immediately after intervention (T1)

    The EORTC QLQ-INFO25 will be used to evaluate participants' satisfaction with the information received. A four-point Likert scale is used to score 25 items ('nothing' = 1 to 'a lot' = 4), with higher scores indicating greater information satisfaction.

  2. Anxiety and stress

    Time frame: Baseline and immediately after intervention (T1)

    The Depression Anxiety Stress Scale-21 (DASS-21) will be used to assess anxiety and stress.(36) 21 items are scored using a four-point Likert scale, with higher score indicating more severe symptoms.

  3. Self-efficacy

    Time frame: Baseline and immediately after intervention (T1)

    Self-efficacy will be assessed using the Strategies Used by People to Promote Health (SUPPH) with good reliability and validity. This 28-item likert scale measure self-care self-efficacy, with higher scores indicating more positive perceptions of self-efficacy.

  4. System Usability Scale

    Time frame: immediately after intervention (T1)

    System Usability Scale (SUS) will be used to measure the usability of digital health solutions by 10 items rated on a 5-point Likert scale from 0-100. The chatbot will be considered highly usable if the mean score exceeds 68.

Study contacts

Contact information is provided by the study sponsor or research team.

Qi LIU, PhD

CONTACT

[email protected]

85255741349

Sponsors and collaborators

Lead sponsor

The Hong Kong Polytechnic University

Other

Collaborators

  • Prince of Wales Hospital, Shatin, Hong Kong
  • Queen Elizabeth Hospital, Hong Kong
  • Queen Mary Hospital, Hong Kong

Registry information

Official study title

The Development and Evaluation of a Co-designed, AI-based Information-providing Chatbot for Sarcoma Patients: A Pilot Randomised Controlled Trial

Important dates

Study start
2027
Primary completion
2028
Study completion
2028
First posted
Apr 1, 2026
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.